Portola Pharmaceuticals Sets New 52-Week High at $31.18 (PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA) reached a new 52-week high on Wednesday , American Banking & Market News reports. The stock traded as high as $31.18 and last traded at $30.89, with a volume of 194,847 shares traded. The stock had previously closed at $30.12.
The stock has a 50-day moving average of $24.57 and a 200-day moving average of $25.35. The company’s market cap is $1.273 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings data on Monday, May 12th. The company reported ($0.75) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.03. The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $1.81 million. During the same quarter last year, the company posted ($12.94) earnings per share. Portola Pharmaceuticals’s revenue was down 23.8% compared to the same quarter last year. Analysts expect that Portola Pharmaceuticals will post $-3.44 EPS for the current fiscal year.
In other Portola Pharmaceuticals news, CEO William Lis unloaded 10,000 shares of the stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $29.23, for a total transaction of $292,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.